Baldueva et al., 2012: Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, UleÄskaia GI, Shchekina LA, Semenova AI, MikhaÄlichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients]. Voprosy onkologii. 2012; 58(2); 212-221. [PubMed: 22774527].
Hu et al., 2022: Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022; 28(4); 689-696. [PubMed: 34862245].
Sarivalasis et al., 2019: Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of translational medicine. 2019; 17(1); 391. [PubMed: 31771601].
|
